Journal of Controlled ReleaseBioengineeringPeer-reviewed journal article
Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and in vivo CAR T-cell engineering
Jianhao ZengiD, Tyler Ellis PappiD, Awurama AkyianuiD, Alejandra Bahena, Lanfranco Leo, Faris HaliloviciD, Hamideh ParhiziD
Abstract
Targeted lipid nanoparticles (tLNPs) enable efficient mRNA delivery to T cells, allowing for in situ generation of chimeric antigen receptor (CAR) T cells without ex vivo manipulation. This strategy has shown promising therapeutical efficacy in preclinical studies of cardiac fibrosis, cancer, and autoimmune diseases. While multiple T-cell surface receptors have been targeted across studies for tLNP-mediated in vivo CAR T-cell generation and exhibit diverse efficiencies, their comparative performance and the mechanisms underlying these differences remain unclear. Here, we systematically compared tLNPs with antibody-based moieties targeting T-cell receptors including CD2, CD4, CD5, CD7, CD8, or a CD4/8 dual-targeting combination under identical conditions, assessing their mRNA delivery efficiency in human T cells and PBMCs in vitro, and subsequently validating the best performer in vivo in humanized mice. Among all moieties tested, CD7-targeting tLNPs achieved the highest mRNA delivery to T cells and efficiently generated functional CAR T cells in vivo. Mechanistic analysis revealed that receptor internalization, rather than the receptor abundance, is the primary determinant of delivery efficiency, a property intrinsic to each receptor and largely independent of antibody clone. These findings provide a rational framework for selecting optimal targeting moiety to enable highly efficient in vivo CAR T-cell engineering. HighlightsO_LITargeting CD7 outperforms other receptors for tLNP-mRNA delivery to T cells C_LIO_LIReceptor abundance does not predict tLNP-mRNA delivery efficiency C_LIO_LIReceptor internalization kinetics governs tLNP-mRNA delivery efficiency C_LIO_LICD7-targeting LNP-mRNA enables efficient in vivo CAR T-cell engineering C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=90 SRC="FIGDIR/small/701374v1_ufig1.gif" ALT="Figure 1"> View larger version (35K): org.highwire.dtl.DTLVardef@9c2c4eorg.highwire.dtl.DTLVardef@120ced7org.highwire.dtl.DTLVardef@eb9b5forg.highwire.dtl.DTLVardef@25b6f7_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: multiome
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: benchmarking
- research focus: protein structure prediction
- approach: experimental assay
- Citations
- 11
- FWCI
- 22.73
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An inherent T cell-activating mRNA delivery platform for in vivo CAR T generation
Qiannan Cao, Yufei Yao, … Huayu Tian·bioRxiv·Nov 19, 2025
- Lipid Nanoparticles with Aptamers Enable Targeted mRNA Delivery to CD4⁺ T Cells
Shrey Shah, Meenakshi Ranasinghe, … Sherwood Yao·Drug DeliveryPeer-reviewed·Feb 27, 2026
- Dual-targeted nanoparticles enable the ex vivo generation of cytotoxic and phagocytic CAR effector cells
Jisu Hong, Jinwoong Lim, … Dohyun Han·bioRxiv·Sep 22, 2026
- DNA-Directed Assembly of Multivalent Lipid Nanoparticles for Targeted T Cell Gene Delivery
Mary D. Kelly, Timothy Q. Vu, … Neha P. Kamat·Journal of Controlled ReleasePeer-reviewed·Mar 29, 2026
- Synthesis of mRNA lipid nanoparticles for engineering GD2 CAR T and CAR NK cells against neuroblastoma
Chih-Chun Chang, Lei Shi, … Jacques Galipeau·bioRxiv·Dec 17, 2025
- Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging
Zihan Zhang, Bin Ma, … Lei Miao·Cell Reports MedicinePeer-reviewed·Jul 1, 2025